Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPH2201 in gynecologic malignancies
NCT02459301Phase 1Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Sep 2015
- Primary completion
- Nov 2017
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of monalizumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 2 more, sponsored by Canadian Cancer Trials Group. Primary endpoint: Recommended Phase 2 Dose at 24 months. Started Sep 2015; status: completed.
02
Drugs
monalizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)Cervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT02459301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02459301.